UCB SA (LON:0NZT)

Market Cap	27.40B
Revenue (ttm)	5.09B
Net Income (ttm)	880.72M
Shares Out	n/a
EPS (ttm)	4.53
PE Ratio	31.11
Forward PE	22.79
Dividend	0.83 (0.52%)
Ex-Dividend Date	Apr 25, 2025

Volume	9,442
Average Volume	58,919
Open	159.03
Previous Close	156.58
Day's Range	156.85 - 159.60
52-Week Range	129.35 - 198.70
Beta	0.26
RSI	61.64
Earnings Date	Jul 31, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 9,378
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZT

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR